1JAU

NMR Solution Structure of the Trp-Rich Peptide of HIV gp41 Bound to DPC Micelles

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D NOESY	1.6 mM synthetic gp41 peptide, 200 mM perdeuterated dodecylphosphocholine	90% H2O/10% D2O	200 mM DPC-d38	3.51	ambient	310
2	2D TOCSY	1.6 mM synthetic gp41 peptide, 200 mM perdeuterated dodecylphosphocholine	90% H2O/10% D2O	200 mM DPC-d38	3.51	ambient	310
3	DQF-COSY	1.6 mM synthetic gp41 peptide, 200 mM perdeuterated dodecylphosphocholine	90% H2O/10% D2O	200 mM DPC-d38	3.51	ambient	310
4	2D NOESY	1.6 mM synthetic gp41 peptide, 200 mM perdeuterated dodecylphosphocholine	100% D2O	200 mM DPC-d38	3.51	ambient	310
5	2D TOCSY	1.6 mM synthetic gp41 peptide, 200 mM perdeuterated dodecylphosphocholine	100% D2O	200 mM DPC-d38	3.51	ambient	310

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	500
2	Varian	INOVA	800

NMR Refinement
Method	Details	Software
distance geometry, simulated annealing, molecular dynamics, matrix relaxation	Structures were initially generated using CNS. Ambiguous and unassigned noe constraints were then used in conjuction with matrix relaxation analysis using the program ARIA.	XwinNMR

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	200
Conformers Submitted Total Number	40

Additional NMR Experimental Information
Details	This structure was determined using standard 2D homonuclear techniques.

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	XwinNMR	2.6	Bruker
2	processing	NMRPipe	1.8	F.Delaglio, S.Grzesiek, G.Vuister, G.Zhu, J.Pfeifer, A.Bax
3	data analysis	NMRView	4.1.3	B.Johnson, R.A.Blevins
4	structure solution	CNS	1.0	A.T.Brunger, P.D.Adams, G.M.Clore, W.L.Delano, P.Gros, R.W.Grosse-Kunstleve, J.-S.Jiang, J.Kuszewski, M.Nilges, N.S.Pannu, R.J.Read, L.M.Rice, T.Simonson, G.L.Warren
5	iterative matrix relaxation	ARIA	1.0	M.Nilges, J.Linge, S.O'Donoghue
6	refinement	CNS	1.0	A.T.Brunger, P.D.Adams, G.M.Clore, W.L.Delano, P.Gros, R.W.Grosse-Kunstleve, J.-S.Jiang, J.Kuszewski, M.Nilges, N.S.Pannu, R.J.Read, L.M.Rice, T.Simonson, G.L.Warren

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.